Last month, the companies announced that Takara Bio USA — formerly Clontech Laboratories and now a subsidiary of Japan's Takara Bio — would acquire WaferGen.
At a user meeting in London this week, Chief Technology Officer Clive Brown introduced the SmidgIon and a number of other technology developments, as well as a new synthetic biology spinoff.
The company will use proceeds from the placement to conduct clinical trials on its Parsortix CTC system, which has been adopted by Cancer Research UK's Mancherster Institute.